v3.23.2
Business - Additional Information (Detail)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2020
May 31, 2018
Jun. 30, 2023
USD ($)
item
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2023
USD ($)
item
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Nature Of Business [Line Items]                  
Date of formation             Jul. 02, 2004    
Proceeds from equity and debt financing     $ 519,600       $ 519,600    
Number of follow-on public offerings | item     4       4    
Payments received in connection with license and supply agreements     $ 279,900       $ 279,900    
Unrestricted cash and cash equivalents and marketable securities     101,744       101,744    
Accumulated deficit     624,376       624,376   $ 566,232
Net loss     $ (31,479) $ (26,665) $ (4,206) $ (27,749) (58,144) $ (31,955)  
Net cash used in operating activities             (55,063) $ (30,028)  
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member]                  
Nature Of Business [Line Items]                  
Percentage of net profit sharing   50.00%              
CSL Vifor [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member]                  
Nature Of Business [Line Items]                  
Percentage of net profit sharing 40.00%                
Vifor International Ltd. [Member]                  
Nature Of Business [Line Items]                  
Proceeds from the sale of common stock under license agreement with Vifor International             $ 98,000    
Vifor Fresenius Medical Care Renal Pharma, Ltd [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member]                  
Nature Of Business [Line Items]                  
Percentage of net profit sharing   50.00%              
CSL Vifor [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member]                  
Nature Of Business [Line Items]                  
Percentage of net profit sharing 60.00%